Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.
Approval Alert | Darolutamide in Metastatic Castration-Sensitive Prostate Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
2
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
3
FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL
4
Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC
5
